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Abstract 
Wolman disease (WD) is an autosomal recessive lysosomal storage disorder, caused by a deficiency of 
lysosomal acid lipase. Affected infants usually develop abdominal distension, hepatosplenomegaly, steatorrhea, 
severe malabsorption and malnutrition, and adrenal calcification. Despite treatment attempts, the clinical 
outcome is poor. We report a case of a 4-month-old girl with WD, presented with a rapidly progressive liver 
failure and a liver transplantation was performed. The graft was retrieved from her mother. The postoperative 
period was uneventful. The child was in a satisfactory condition about 8 weeks after surgery and the enzyme 
replacement therapy (ERT) was started. During the treatment weight loss and vomiting persisted and a diarrhea 
started. Patient died due to severe respiratory failure seven weeks after starting ERT. 
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1. Introduction  
Wolman disease is an extremely rare autosomal recessive lysosomal storage disorder, caused by mutations in 
the LIPA gene that maps to chromosome 10q23.2-q23.3 and encodes lysosomal acid lipase (LAL).  
------------------------------------------------------------------------ 
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Many mutations of LIPA gene have been found in Wolman disease patients and bring about an absence of LAL 
activity. The deficiency of LAL leads to the accumulation of cholesteryl esters and triglycerides in various 
tissues and organs. WD is the most severe form of LAL deficiency, a milder form is known as cholesteryl ester 
storage disease (CESD). A lot of mutations of LIPA in CESD allow the expression of significant residual LAL 
activity. The symptoms of WD appear during the first few months of life. Affected infants usually develop 
abdominal distension, hepatosplenomegaly, steatorrhea, severe malabsorption and malnutrition, and adrenal 
calcification. The symptoms get progressively worse and lead to life-threatening complications during infancy 
including severe anemia, cachexia and liver failure. Despite treatment attempts (enzyme replacement therapy, 
parenteral nutrition, steroids, dietary supplements, hematopoietic stem cells transplantation, liver 
transplantation), the clinical outcome is poor [1]. We report a case of a liver transplantation (LT) in a recipient 
with WD. 
2. Case presentation 
A female infant, first child of nonconsanguineous parents with no family history, was born at 37 weeks’ 
gestation with birth weight of 2.4 kg and a length of 47 cm. The baby developed frequent episodes of vomiting, 
failure to thrive, and anemia, accompanied by gradual abdominal distension within the first few weeks of life. 
At 3 months of age, after consultation with a hematologist, she was referred to Department of Clinical Genetics 
with a suspicion of a lysosomal storage disease. On admission her weight, height, and head circumference were 
under the 3rd percentile for age. On physical examination there was pallor, generalized edema and 
hepatosplenomegaly – liver edge was palpable about 4 cm from the right costal ridge and the spleen was 
palpable 5 cm below the left costal margin. Initial investigations revealed evidence of liver dysfunction with 
elevated activity of transaminases, conjugated hyperbilirubinemia, hypoproteinemia, hypoalbuminemia, 
hypofibrynogenaemia and low serum levels of alpha-1 antitrypsin.  
The total cholesterol and triglyceride were normal. Prothrombin time was prolonged with INR of 3.75. The 
complete blood count result showed microcytic and hypochromic anemia and thrombocytopenia. Serologic tests 
for cytomegalovirus, human immunodeficiency virus, toxoplasmosis, herpes simplex virus, rubella and hepatitis 
B and C virus were negative. Elevated plasma chitotriosidase activity of 1830 nmol/ml/h (5-60) was detected, 
indicating macrophage accumulation. The levels of sphyngomyelinase, beta-glucosidasae, beta-galactosidase 
and lyso-SM-509 were within normal limits. Echocardiography and transfontanellar ultrasound were 
unremarkable. Abdominal ultrasonography (US) showed an enlarged liver with increased parenchymal 
echogenicity, signs of portal hypertension, splenomegaly and mild pelvic ascites. Computed tomography (CT) 
of the abdomen and pelvis confirmed the previous findings at US, but calcified and symmetrically enlarged 
adrenal glands were also noted (Fig.1-2). 
In view of adrenal calcification and clinical symptoms the diagnosis was narrowed down to WD. For the 
confirmation of diagnosis, LAL activity in peripheral leukocytes was measured and was found to be 38 
nmolMU/h/mg (135-530). DNA sequencing of the LIPA gene demonstrated that the patient was homozygous 
for a known splice site mutation c.822+1G>A. Both parents were heterozygous carriers of the mutation. 
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Figure 1: Enlarged adrenal glands with calcificationon CT 
 
Figure 2: Hepatomegaly and adrenal gland calcification on CT 
At 4 month̓̓
̓̓̓
̓̓
’s age the baby had severerapidly progressive hepatic dysfunction and was referred to a 
transplantation center, where an emergency living donor liver transplantation was performed.  
The child received a segment II and III hepatic graft weighing 320 grams from the left lobe of his mother’s 
liver. She was extubated 8 hours later in the intensive care unit. During an uneventful postoperative period, the 
hepatic function normalized (Table 1). The immunosuppressive regimen was based on Tacrolimus and 
Methylprednisolone. 
Gradually the child improved clinically and was discharged in a satisfactory condition about 8 weeks after 
surgery and was transferred to Department of Clinical Genetics, where the enzyme replacement therapy with 
Sebelipase alpha (Kanuma, SynagevaBioPharma Corporation, Lexington, Massachusetts, USA) was started. 
The starting dose was 1 mg/kg weekly intravenously and was gradually increased to 3 mg/kg weekly due to the 
lack of a clinical response. During the treatment weight loss and vomiting persisted and a diarrhoea started. 
Patient died due to severe respiratory failure seven weeks after starting ERT.  
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Table 1: Chronological changes in laboratory test results 
 
ALT alanine transaminase, AST aspartate transaminase, T-Bil total bilirubin, D-Bil direct bilirubin, GGT 
gamma-glutamyl transferase, PT prothrombin time, INR international normalized ratio  
3. Discussion  
WD is a progressive disorder and usually it is fatal. It leads to a death before 1 year of age. The symptoms are 
apparent within the first months postpartum. Current management of LAL deficiency (LALD) focuses on lipid 
control and improvement of liver complications. The nutritional support and the blood transfusions are included 
in the supportive intervention. Corticosteroid and mineralocorticoid replacement is indicated in the presence of 
adrenal insufficiency. 
ERT has proven effective and now is the treatment of choice for patients with lysosomal storage disorders 
without central nervous system involvement [2]. The orphan drug Kanuma (sebelipase alfa) was approved by 
the U.S. Food and Drug Administration (FDA) in December, 2015 for the treatment of LALD (WD and CESD). 
Data from clinical trials showed that the recombinant human LAL enzyme significantly reduced liver volume, 
lipid and transaminase levels [3]. Hematopoietic stem cell transplantation (HSCT) has had mixed results [4]. 
The LT can be considered for individuals who progress to cirrhosis and liver failure and requires further study. 
There are only several reports of LT in patients with LALD [1,5,6,7,8]. Ambler and his colleagues present the 
first published case of successful LT in an adult with CESD, with excellent liver function and a normal lipid 
profile 2 years later [9]. Simon J. and his colleagues confirm that the clinical outcome is poor for infants with 
LALD, despite variations in treatment attempts (HSCT and LT) [1]. 
In our case, because of the rapidly progressive, life-threatening liver failure and an impossibility to start ERT 
 Before LT After LT 1st day After LT 10st day At discharge 
Hemoglobin (g/L) 95 97 92 111 
White cell count (/mm³) 4.6 1.0 10.8 9.6 
Platelet (/mm³) 82 60 227 312 
ALT (IU/L)124 124 268 22 34 
AST (IU/L) 222 290 20 42 
Alkaline phosphatase (IU/L) 291 46 40 105 
T- Bil (mg/dL) 156 47 14 5 
D- Bil (mg/dL) 97 26.2 6.4 2.8 
GGT (IU/L) 45 30 19 20 
Total Protein (g/L) 62.5 40 45 43 
Albumin (g/L) 32 25 33 24 
PT (sec) 41.3 19 16 25.7 
INR 3.63 1.86 1.37 2.1 
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immediately after diagnosis establishment (for administrative and financial reasons), living donor liver 
transplantation has been performed. It was successful, but LALD persisted in other tissues after the procedure 
and the outcome was poor. The cause of death was the progression of WD.  It is incorrectly to comment the 
results from ERT in our patient because the laboratory markers (lipids and transaminases) were in normal range 
at the beginning of ERT and because the period of treatment was very short. Very early onset within the first 
few weeks of life and an aggressive course of disease in our case were additional unfavorable factors. All 
patients included in clinical trials were with milder presentation [3]. 
4. Conclusion 
LT was a life-saving treatment rather than a cure for WD. WD is a progressive disorder and perhaps the 
response to ERT is influenced by the severity of the phenotype at treatment initiation.  
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